| Title |
Adverse Events of Pirfenidone for the Treatment of Pulmonary Fibrosis: A Meta-Analysis of Randomized Controlled Trials
|
|---|---|
| Published in |
PLOS ONE, October 2012
|
| DOI | 10.1371/journal.pone.0047024 |
| Pubmed ID | |
| Authors |
Chunguo Jiang, Hui Huang, Jia Liu, Yanxun Wang, Zhiwei Lu, Zuojun Xu |
| Abstract |
Pirfenidone (PFD) is a novel antifibrotic agent approved for patients with pulmonary fibrosis. However, there are concerns regarding toxicity of the drug. In this meta-analysis, we analyzed the adverse events (AEs) of PFD for the treatment of pulmonary fibrosis. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| Portugal | 1 | 2% |
| France | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 53 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 23% |
| Student > Bachelor | 12 | 21% |
| Other | 8 | 14% |
| Student > Ph. D. Student | 7 | 12% |
| Student > Master | 6 | 11% |
| Other | 7 | 12% |
| Unknown | 4 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 49% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 9% |
| Agricultural and Biological Sciences | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Business, Management and Accounting | 2 | 4% |
| Other | 9 | 16% |
| Unknown | 7 | 12% |